Prometheus Biosciences Catapults 176% On Promising Results In Irritable Bowel DiseaseInvestors Business Daily • 12/07/22
Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAbGlobeNewsWire • 12/07/22
Prometheus Biosciences, Inc. (RXDX) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/09/22
Prometheus Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate ProgressGlobeNewsWire • 11/09/22
Prometheus Biosciences Receives FDA Clearance of IND Application for its Second Precision Program, PRA052GlobeNewsWire • 10/03/22
Prometheus Biosciences, Inc. (RXDX) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/11/22
Prometheus Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate ProgressGlobeNewsWire • 08/11/22
Prometheus Biosciences to Host a Virtual R&D Day for Analysts and Investors on July 26, 2022GlobeNewsWire • 07/18/22
Prometheus Biosciences Completes Enrollment of the ARTEMIS-UC Cohort 1 Phase 2 Study in Ulcerative ColitisGlobeNewsWire • 07/18/22
Prometheus Biosciences Provides Enrollment Update in APOLLO-CD and ARTEMIS-UC Global Phase 2 StudiesGlobeNewsWire • 06/08/22
Prometheus Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate ProgressGlobeNewsWire • 05/12/22
Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)GlobeNewsWire • 03/30/22
Prometheus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate ProgressGlobeNewsWire • 03/09/22
Prometheus Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewsWire • 02/07/22
Prometheus Biosciences to Present at the 40th Annual J.P. Morgan Virtual Healthcare ConferenceGlobeNewsWire • 01/05/22